Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a report issued on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a buy rating and set a $9.00 price target on shares of Trevena in a research note on Tuesday, April 2nd.

Trevena Price Performance

TRVN stock opened at $0.40 on Tuesday. Trevena has a 12-month low of $0.30 and a 12-month high of $3.28. The company has a quick ratio of 4.66, a current ratio of 4.66 and a debt-to-equity ratio of 8.35. The company has a market cap of $7.33 million, a price-to-earnings ratio of -0.13 and a beta of 1.10. The company has a 50 day moving average of $0.47 and a two-hundred day moving average of $0.57.

Trevena (NASDAQ:TRVN) last released its earnings results on Monday, April 1st. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter. The business had revenue of ($0.08) million for the quarter, compared to the consensus estimate of $0.09 million. On average, equities analysts anticipate that Trevena will post -1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Trevena stock. Jump Financial LLC purchased a new position in shares of Trevena, Inc. (NASDAQ:TRVN) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 44,396 shares of the biopharmaceutical company’s stock, valued at approximately $27,000. Jump Financial LLC owned about 0.32% of Trevena as of its most recent SEC filing. Institutional investors own 13.56% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.